Business Wire

KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents

23.4.2026 09:02:00 CEST | Business Wire | Press Release

Share

KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use.

Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance

As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At present, three major bottlenecks are limiting the ability of AI agents to deliver consistent performance and sustainable ROI:

  1. Wasted Capacity: Traditional one-model-per-GPU deployment approaches often result in significant resource underutilization, particularly when auxiliary models such as embedding and OCR are included, ultimately driving up operational costs.
  2. Latency and Execution Failures: Multi-step AI agent workflows are highly sensitive to fluctuations in inference performance. Even minor spikes in inference response latency can interrupt execution logic and cause task failures in long-duration or multi-stage workflows.
  3. Management Complexity: Fragmented model APIs, diverse security requirements, and fluctuating compute demands across different AI agents can significantly increase operational complexity, placing mounting pressure on DevOps and IT teams.

MotusAI: The Intelligent Brain Behind AI Agents

MotusAI delivers a high-availability architecture that decouples agent logic from model inference, providing four clear and tangible benefits for enterprise users:

  1. Maximize Infrastructure ROI: By unlocking resource sharing across model workloads, MotusAI enables dynamic GPU utilization at scale. Enterprises can deploy and support far more AI agent instances on the same infrastructure, boosting compute efficiency, increasing return on investment, and reducing total cost of ownership (TCO).
  2. Guaranteed Task Continuity: MotusAI enables stable, continuous AI agent operations through SLA-grade monitoring of critical inference metrics such as TTFT (Time to First Token) and TPOT (Time Per Output Token). Combined with automatic elastic scaling, this capability helps AI agents reduce latency, prevent task disruptions, and deliver a smoother, more dependable user experience during traffic surges and peak demands.
  3. Accelerated Time-to-Market: MotusAI’s centralized Model Hub includes pre-integrated support for more than 50 mainstream open-source models, such as Llama 3, Mistral, and DeepSeek. Combined with a unified API gateway, it allows developers to rapidly select and deploy best-fit model capabilities for AI agents, reducing integration time from days to minutes.
  4. Precision Cost Management: With task-level cost tracking, MotusAI gives enterprises precise visibility into the compute cost of every AI agent mission, helping them clearly evaluate the investment required for individual AI workflows.

MotusAI and OpenClaw Integration: A Three-Step Framework

To bring these benefits into production, MotusAI delivers deep integration with OpenClaw, an emerging open-source framework for AI agents. Through a streamlined three-step operation, enterprises can progress from initial integration to fully operational AI agent deployment:

  1. Optimized Decoupling: OpenClaw manages task orchestration and execution logic on standard x86 servers, while MotusAI handles compute-intensive model inference to AI servers. This “brain-body” separation enables independent optimization of orchestration and inference workloads, ensuring that each subsystem operates on the substructure best aligned with its functional requirements.
  2. Seamless No-Code Integration: With one-click LLM deployment through MotusAI, users can connect OpenClaw to the MotusAI unified API and instantly equip AI agents with enterprise-grade compute power, without any code modifications.
  3. Automated Performance Optimization: MotusAI provides real-time load balancing and dynamic resource reclamation, enabling OpenClaw agents to remain focused on execution logic, while the platform itself continuously optimizes backend resource allocation based on live workload conditions.

Conclusion

As AI agents emerge as a core engine of digital productivity, the need for a stable and efficient compute foundation becomes indispensable. With the advanced orchestration capabilities of MotusAI and its integration with the OpenClaw framework, KAYTUS is providing the essential infrastructure required to translate AI agent potential into dependable, scalable, and enterprise-ready business value.

About KAYTUS

KAYTUS is a leading provider of AI infrastructure and liquid cooling solutions, delivering a diverse range of innovative, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com and follow us on LinkedIn and X

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423471448/en/

Contacts

Media Contacts
media@kaytus.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press Release

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. FDA Fast Track designation expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423262096/en/ First

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press Release

Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency with the latest technology. Strategic Partnership with Medfile The joint

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press Release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press Release

Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues, an increase of 8.2% at constant exchange rates (CER) compared to 2024. EBITDA reached €931 million (25.7%). Chiesi closed 2025 with a positive Net Financial Position (cash minus financial liabilities including leasing) of €729 million, improving by €194 million versus 2024, reconfirming the Group’s capacity to self‑finance its investment strategy. The Group’s three therapeutic areas – Respiratory (Air), Rare Diseases (Rare), and Specialty Care (Care) – all contributed well to the year’s sales. A strong performance in the Global Rare Disease business unit saw sales increase to €906 million, +22.3% at CER, representing 50% of total Group growth across the U.S., Europe and international markets. The Air franchise sales reached €1.886 billion, up 3.9% at

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press Release

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for the year 2024. The Group net profit was at €250.9 million. In 2024, the corresponding figure was €211.1 million. The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposals formulated by the Board of Directors: Authorization to purch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye